Could BRAF be a new target in NSCLC?

Could BRAF be a new target in NSCLC?

Da: GRACEcast
0 0 7 anni fa
Drs. Nate Pennell, Mary Pinder, and Jack West discuss an encouraging study of dabrafenib, a BRAF inhibitor, for the limited number of NSCLC patients with a BRAF V600E mutation.

Seguici su Facebook